Two Sigma Investments — ALNY Trade History

Quarter-by-quarter changes in the ALNYLAM PHARMACEUTICALS INC position · CUSIP 02043Q107
Currently held · 2.5 YearsFirst seen: 2017 Q2
QuarterFiledActivitySharesΔ SharesΔ %Value% Port.
2026 Q22026-08-14Reduce1,875,937-116,640-5.9%$564.7M0.41%
2026 Q12026-05-15Add1,992,5771,376,457+223.4%$659.3M0.53%
2025 Q42026-02-17Add616,12020,194+3.4%$245.0M0.35%
2025 Q32025-11-14Add595,926252,621+73.6%$271.7M0.41%
2025 Q22025-08-14Add343,305145,890+73.9%$111.9M0.20%
2025 Q12025-05-15Add197,41590,298+84.3%$53.3M0.11%
2024 Q42025-02-14Add107,11787,969+459.4%$25.2M0.06%
2024 Q32024-11-14Reduce19,148-83,770-81.4%$5.3M0.01%
2024 Q22024-08-14Add102,918406+0.4%$25.0M0.06%
2024 Q12024-05-15New102,512102,512$15.3M0.04%
2023 Q42024-02-14Sold out-3,300-100.0%
2023 Q32023-11-14Reduce3,300-221,369-98.5%$584.4K0.00%
2023 Q22023-08-14Add224,66957,323+34.3%$42.7M0.11%
2023 Q12023-05-15Reduce167,346-15,361-8.4%$33.5M0.10%
2022 Q42023-02-14Reduce182,707-34,005-15.7%$43.4M0.14%
2022 Q32022-11-14New216,712216,712$43.4M0.15%
2022 Q22022-08-15Sold out-73,949-100.0%
2022 Q12022-05-16New73,94973,949$12.1M0.04%
2021 Q42022-02-14
2021 Q32021-11-15
2021 Q22021-08-16Sold out-36,619-100.0%
2021 Q12021-05-17New36,61936,619$5.2M0.01%
2020 Q42021-02-16
2020 Q32020-11-16
2020 Q22020-08-14
2020 Q12020-05-15
2019 Q42020-02-14
2019 Q32019-11-14
2019 Q22019-08-14
2019 Q12019-05-15
2018 Q42019-02-14Sold out-20,675-100.0%
2018 Q32018-11-14Reduce20,675-102,708-83.2%$1.8M0.01%
2018 Q22018-08-14Reduce123,383-132,993-51.9%$12.2M0.04%
2018 Q12018-05-15Reduce256,376-46,000-15.2%$30.5M0.10%
2017 Q42018-02-14Add302,376158,502+110.2%$38.4M0.13%
2017 Q32017-11-14Add143,874141,127+5137.5%$16.9M0.06%
2017 Q22017-08-14New2,7472,747$219.0K0.00%
2017 Q12017-05-15
2016 Q42017-02-14
2016 Q32016-11-14

Share counts are split-adjusted. Time held counts consecutive quarters ending with the latest filing; more than ten years shows as ">10 Years".

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.